Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw strong trading volume on Wednesday . 1,615,825 shares traded hands during trading, an increase of 318% from the previous session’s volume of 386,653 shares.The stock last traded at $9.83 and had previously closed at $9.73.

Several equities analysts have recently commented on the company. S&P Equity Research cut their price target on Karyopharm Therapeutics from $9.06 to $7.55 in a research note on Tuesday. Jefferies Group upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $9.00 to $12.00 in a research note on Tuesday. HC Wainwright assumed coverage on Karyopharm Therapeutics in a research note on Thursday, August 18th. They set a “buy” rating and a $15.00 price target on the stock. Zacks Investment Research lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Finally, Canaccord Genuity set a $20.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Saturday, August 6th. Two research analysts have rated the stock with a sell rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.35.

The firm has a 50 day moving average of $7.29 and a 200 day moving average of $7.95. The firm’s market capitalization is $358.09 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.08. On average, analysts forecast that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current year.

In other news, major shareholder Ltd Chione sold 45,541 shares of the firm’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $9.21, for a total transaction of $419,432.61. Following the sale, the insider now owns 8,605,818 shares in the company, valued at $79,259,583.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.